Targeted Medical Pharma Announces New Partnership for Exclusive Distribution in Japan
20 February 2015 - 5:00AM
Business Wire
Targeted Medical Pharma (OTCQB: TRGM) today announced the
completion of an exclusive product distribution agreement with
J-Network Inc., a California-based company that specializes in
distributing cosmetic and healthcare goods exclusively to
Japan.
The Agreement grants J-Network an exclusive one-year renewable
license for the marketing and sales of the Company’s proprietary
product, designed to improve sleep and immune function, in Japan.
Under the terms of the Agreement, Targeted Medical Pharma will
develop new products specific for import into the Japanese market,
and J-network is responsible for a guaranteed initial order of
360,000 capsules as well as maintaining annual minimum purchase
orders of 1.4 million capsules for the first two years, and 2.1
million capsules thereafter.
This is the second partnership between Targeted Medical Pharma
and J-Network. From 2007 to 2011, the J-Network successfully
marketed Targeted Medical Pharma’s products to a variety of
consumer groups throughout Japan.
“The completion of this agreement represents management's
renewed commitment to developing new revenue-generating
opportunities abroad,” said Kim Giffoni, Chief Executive at
Targeted Medical Pharma. “J-Network is a reliable and honorable
business partner who understands the value of our product line and
has a successful track record of distributing our products in
Japan.”
Connect with us on Google Plus, Linkedin, Twitter and
Facebook.
About Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc. is a Los Angeles-based
biotechnology company that develops medical foods for the treatment
of chronic disease, including pain syndromes, peripheral
neuropathy, hypertension, obesity, sleep and cognitive disorders.
The company also develops a line of dietary supplements designed to
support health and wellness. The company manufactures 10
proprietary medical foods, and the dietary supplement for sinus and
immune support, Clearwayz™. The products are sold directly to
physicians, patients and pharmacies in the United States and
abroad.
Forward-Looking Statement
This press release may contain forward-looking statements
related to Targeted Medical Pharma’s business strategy, outlook,
objectives, plans, intentions or goals. Targeted Medical Pharma
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statement contained herein to reflect
any change in the company's expectations with regard thereto or any
change in events, conditions or circumstances upon which any
statement is based.
Company Contact:Targeted
Medical PharmaMarcus Charuvastra,
310-474-9809marcusch@tmedpharma.comorInvestor Contact:Targeted Medical
PharmaWilliam B. Horne, 310-474-9809whorne@tmedpharma.com
Targeted Medical Pharma (CE) (USOTC:TRGM)
Historical Stock Chart
From Jan 2025 to Feb 2025
Targeted Medical Pharma (CE) (USOTC:TRGM)
Historical Stock Chart
From Feb 2024 to Feb 2025
